Changes in oncogenic protein levels in peri-implant oral malignancy: a case report
10.1186/s40902-019-0235-z
- Author:
Mi Hyun SEO
1
,
2
;
Hoon MYOUNG
;
Jong Ho LEE
;
Soung Min KIM
;
Suk Keun LEE
Author Information
1. Department of Oral and Maxillofacial Surgery, Dental Research Institute, School of Dentistry, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul 110-768, South Korea. smin5@snu.ac.kr
2. smin_kim@msn.com
- Publication Type:Case Report
- From:Maxillofacial Plastic and Reconstructive Surgery
2019;41(1):46-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND:Oral squamous cell carcinoma (OSCC) constitutes a group of tumors that exhibit heterogeneous biology, histopathology, and clinical behaviors.CASE PRESENTATION: A 73-year-old male had a whitish leukoplakia-like lesion around inflamed peri-implant area (#42, #43, and #44), and this lesion had transformed to OSCC within 3Â years. He underwent mass resection, selective neck dissection, and reconstructive surgery. To detect any carcinogenesis progression, we examined the removed tumor tissue as well as the patient's preoperative and postoperative sera to identify causative oncogenic proteins using immunoprecipitation high-performance liquid chromatography (IP-HPLC).
CONCLUSIONS:The protein expression levels of p53, E-cadherin, β-catenin, MMP-10, HER2, NRAS, Met, HER2, and ERb were significantly lower in the serum collected on postoperative day 10 than in the preoperative serum, and if these proteins are consistently not elevated in the serum 3 months after surgery compared with the preoperative serum, these proteins can be potential oncogenic proteins. However, we also found that the serum extracted 3 months after the operation had elevated levels of oncogenic proteins compared with that of the preoperative and 10-day postoperative serum indicating the possibility of tumor recurrence. At postoperative follow-up period, ipsilateral neck metastasis and second primary lesion were found and additional surgery was performed to the patient. IP-HPLC using the patient's serum shows the possibility of oncogenic protein detection. However, follow-up IP-HPLC data is needed to find out patient-specific prognostic factors.
